129 related articles for article (PubMed ID: 23856341)
1. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.
Tørring C; Petersen CC; Bjerg L; Kofod-Olsen E; Petersen T; Höllsberg P
J Neuroimmunol; 2013 Sep; 262(1-2):92-9. PubMed ID: 23856341
[TBL] [Abstract][Full Text] [Related]
2. Memory and naïve B-cell subsets in patients with multiple sclerosis.
Niino M; Hirotani M; Miyazaki Y; Sasaki H
Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
[TBL] [Abstract][Full Text] [Related]
3. B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Rovituso D; Heller S; Schroeter M; Kleinschnitz C; Kuerten S
J Neuroimmunol; 2014 Jul; 272(1-2):86-90. PubMed ID: 24814390
[TBL] [Abstract][Full Text] [Related]
4. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
[TBL] [Abstract][Full Text] [Related]
5. Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients.
Giovanni F; Domenico P; Alessandro M; Raffaele I; Viviana N; Katia PA; Paola BA
J Neuroimmunol; 2011 Dec; 240-241():137-41. PubMed ID: 22001684
[TBL] [Abstract][Full Text] [Related]
6. Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis.
Mikulkova Z; Praksova P; Stourac P; Bednarik J; Michalek J
J Neurol Sci; 2011 Jan; 300(1-2):135-41. PubMed ID: 20884014
[TBL] [Abstract][Full Text] [Related]
7. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.
Lisak RP; Benjamins JA; Nedelkoska L; Barger JL; Ragheb S; Fan B; Ouamara N; Johnson TA; Rajasekharan S; Bar-Or A
J Neuroimmunol; 2012 May; 246(1-2):85-95. PubMed ID: 22458983
[TBL] [Abstract][Full Text] [Related]
8. High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis.
Levy YA; Fainberg KM; Amidror T; Regev K; Auriel E; Karni A
J Neuroimmunol; 2013 Apr; 257(1-2):82-9. PubMed ID: 23466131
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Farhum F; Karni A
J Neurol Sci; 2010 Aug; 295(1-2):31-7. PubMed ID: 20541775
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
Krumbholz M; Meinl I; Kümpfel T; Hohlfeld R; Meinl E
Neurology; 2008 Oct; 71(17):1350-4. PubMed ID: 18936427
[TBL] [Abstract][Full Text] [Related]
11. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
[TBL] [Abstract][Full Text] [Related]
13. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
[TBL] [Abstract][Full Text] [Related]
14. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis.
McKay FC; Swain LI; Schibeci SD; Rubio JP; Kilpatrick TJ; Heard RN; Stewart GJ; Booth DR
J Autoimmun; 2008 Aug; 31(1):52-8. PubMed ID: 18406576
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
16. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.
Knippenberg S; Peelen E; Smolders J; Thewissen M; Menheere P; Cohen Tervaert JW; Hupperts R; Damoiseaux J
J Neuroimmunol; 2011 Oct; 239(1-2):80-6. PubMed ID: 21940055
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotyping of putative human B1 B cells in healthy controls and common variable immunodeficiency (CVID) patients.
Suchanek O; Sadler R; Bateman EA; Patel SY; Ferry BL
Clin Exp Immunol; 2012 Dec; 170(3):333-41. PubMed ID: 23121674
[TBL] [Abstract][Full Text] [Related]
18. Low and dysregulated production of follistatin in immune cells of relapsing-remitting multiple sclerosis patients.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Karni A
J Neuroimmunol; 2011 Sep; 238(1-2):96-103. PubMed ID: 21880375
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with relapsing-remitting multiple sclerosis.
Bilińska M; Frydecka I; Podemski R; Teodorowska R; Gruszka E
Med Sci Monit; 2001; 7(2):251-5. PubMed ID: 11257731
[TBL] [Abstract][Full Text] [Related]
20. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.
Bjerg L; Brosbøl-Ravnborg A; Tørring C; Dige A; Bundgaard B; Petersen T; Höllsberg P
J Neuroimmunol; 2012 Aug; 249(1-2):76-82. PubMed ID: 22608884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
